XML 84 R62.htm IDEA: XBRL DOCUMENT v3.25.1
SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2024
Aug. 01, 2023
Feb. 28, 2023
Apr. 30, 2022
Dec. 31, 2024
Dec. 31, 2023
Jun. 12, 2024
Apr. 04, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Number of shares issued, value         $ (75,000) $ 911,371    
Payment in cash           3,089,645    
Options to acquire shares       144,191      
Weighted exercise price       $ 10.71        
Warrants to purchase shares       4,424        
Exercise price       $ 7.32        
Expiration date       Apr. 22, 2031        
Restricted stock award, gross         $ 5,747,656      
Share-based compensation         4,436,048 3,442,722    
Unrecognized share-based compensation expense $ 4,189,272       $ 4,189,272      
Unrecognized share-based compensation expense period for recognition         1 year 6 months      
Precision Healing [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Payment in cash       $ 600,000        
Share price       $ 27.13        
Accredited Investors [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Issuance of shares       165,738        
Nonaccredited Investors [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Share price               $ 30.75
Precision Healing Inc [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Cash consideration       $ 125,966        
Payment of contingent consideration       $ 10,000,000.0        
Common Stock [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Number of shares issued, value         $ 26    
Sale of stock         26,143    
Issuance of shares           73,809    
Payment in cash           $ 74    
Warrants to purchase shares       12,301        
Exercise price       $ 12.05        
Expiration date       Aug. 10, 2030        
Applied Asset Purchase Agreement [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Shares issued as consideration   73,809            
Cash consideration   $ 16,792,037            
Payment of contingent consideration   $ 893,000            
Applied Asset Purchase Agreement [Member] | Stock Closing Consideration [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Shares issued as consideration   73,809            
Sales Agreement [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Number of shares issued, value     $ 75,000,000          
Sales Agreement [Member] | Common Stock [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Number of shares issued, value           $ 1,100,000    
Sale of stock           26,143    
Net proceeds           $ 900,000    
2024 Omnibus Long-Term Incentive Plan [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Maximum number of shares available for grant             1,000,000  
Number of shares issued 2,543              
Number of shares available for issuance 1,000,137       1,000,137      
Stock granted and issued         2,543      
2024 Omnibus Long Term Incentive Plan [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Number of shares issued 742,405              
Stock granted and issued         161,908